Google+ Facebook Twitter Twitter

Tech news: February 2023

This month's top tech news stories

Nykode Therapeutics

Manufacturing  partnership

Nykode Therapeutics, a clinical-stage biopharmaceutical company, has entered into a strategic manufacturing partnership with Richter-Helm to supply plasmid DNA for Nykode’s wholly owned and partnered product portfolio. “As a leading manufacturer of DNA vaccines, they will provide the long-term expertise and capacity needed to support our ambitious growth and pipeline development,” said Mette Husbyn, Nykode Therapeutics Chief Technology Officer.

Sheffield Teaching Hospitals

Cardiovascular diagnostics

An artificial intelligence (AI) tool that provides a quick and comprehensive analysis of the heart’s function could improve future cardiovascular care by aiding earlier diagnosis and giving more detailed information about the heart’s function. Developed by researchers at Sheffield Teaching Hospitals NHS Foundation Trust and the University of Sheffield, the tool detects chambers of the heart on MRI images – performing in seconds tasks that would involve lengthy manual analysis.


LGC Clinical Diagnostics

Diabetes Kit

LGC Clinical Diagnostics announced the addition of Cystatin C to Maine Standards Validate diabetes kit for the Roche cobas platforms for easy, fast, reliable documentation of linearity and calibration verification. The product – with the analytes Beta-Hydroxybutyrate, C-Peptide, Insulin, Fructosamine, and now Cystatin C – is formulated in human serum, using the CLSI EP06 “equal delta” sample preparation method, and provides five distinct concentrations. Validate diabetes test kits are frozen liquid and ready to use – dispense the solution from each dropper bottle, directly into five sample cups, and run in replicates to verify the assay’s reportable range.


Image credit | Shutterstock | Sheffield Teaching Hospitals NHS Foundation Trust

Related Articles

COVID-19 immune response over time

Immunity from COVID-19 appears to gather strength with more time between vaccination and infection, a new laboratory study from researchers at Oregon Health & Science University (OHSU) suggests. The findings carry implications for vaccine recommendations as the pandemic transitions to an endemic state.

One health: seeing the whole ecosystem

With One Health gaining increasing prominence in research and the media, we look at the driving factors behind the concept and ask what action may need to be taken.

Vaccine protects against brain damage

Although the pathology of the respiratory system is the main impact of COVID-19, many patients manifest important neurological symptoms, such as anosmia, headaches, malaise, cognitive loss, epilepsy, ataxia and encephalopathy.

Insulin: the effect of climate change on medicine

Nigel Crossland argues that we need to revisit manufacturer advice and approaches to insulin, particularly with temperatures increasing.